With the release of the movie "I am not the God of medicine" in China, many netizens have paid attention to cancer as a special group, so are anti-cancer drugs included in the medical insurance in China? The National Health Insurance Bureau has made it clear that it will promote the price reduction of anti-cancer drugs, so that the masses can use good drugs.
The reporter learned from the national medical security bureau that with the gradual implementation of the new regulations on anticancer drugs, relevant departments are actively implementing the follow-up measures to reduce the tax on anticancer drugs, urging and promoting the acceleration of the price reduction of anticancer drugs, so that the masses have more sense of access.
In 2017, 15 cancer drugs with definite curative effect but relatively expensive price, such as Herceptin, rituximab and Vanke, were included in the list of medical insurance drugs. For the anticancer drugs in the catalogue, the next step will be to carry out special bidding procurement, and on the basis of fully considering the impact of tax reduction, realize price reduction through market competition.
How to reduce the price of anticancer drugs out of the medical insurance catalog? The State Medical Insurance Bureau will carry out access negotiations, negotiate with enterprises to determine a reasonable price, and then include it into the catalog, effectively balancing the clinical needs of patients, reasonable profits of enterprises and fund bearing capacity.
It is understood that in recent years, relevant departments have taken a series of measures. In 2017, the proportion of personal expenditure of residents in the total cost of health dropped to 28.8%, 12 percentage points lower than before the new round of medical reform. In terms of anticancer drugs, the vast majority of commonly used and effective drugs have been included in the scope of medical insurance payment.
The state health insurance bureau will press ahead with the work as required, strive to make the masses have access to and can afford good drugs early, and gradually reduce the burden of medical expenses for patients with major diseases.